Jonas from Singapore

Registered at the short selling broker eToro, 3 minutes ago.

» Try eToro you too
67% of retail investor accounts lose money when trading CFDs with etoro.
Don't show again

TG Therapeutics, Inc. (TGTX) shares information

TG Therapeutics Inc


24h Change

-2.78 %

TGTX

Live rate: Market closed

Stock data per Friday 24 Sep, 2021

TGTX
NASDAQ
33.08
32.92
32.16
-0.92 (-2.78%)
US Market is closed

Live Stock price in graph for TG Therapeutics Inc (TGTX)

  • Latest Volume

    957,417 (-2.15 %)

  • Volume prev. day

    978,436

  • Avg. daily volume

    1,524,827

  • Market cap

    4,549,622,361

  • P/E ratio

    -11.82

  • Today high

    33.31 USD

  • Today low

    32.01 USD

  • 52 week high

    56.74 USD

  • 52 week low

    21.06 USD

  • YTD Change

    n/a

Quick links

 

Latest news about TG Therapeutics Inc

Below you can find the most recent news posts about TG Therapeutics Inc, primarily from US and UK based news sources.

TG Therapeutics highlights safety results from Ukoniq lymphoma trials

Thursday, 23 September 2021, 18:52:20
No summary available.
— Seeking Alpha


TG Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference

Thursday, 23 September 2021, 13:30:00
Fireside chat scheduled for 10:40 AM ET on Monday, September 27, 2021 Fireside chat scheduled for 10:40 AM ET on Monday, September 27, 2021
— Intrado Digital Media


TG Therapeutics Announces Combination Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)

Monday, 20 September 2021, 13:30:00
NEW YORK, Sept. 20, 2021 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX ), today announced data presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL). Data highlights from each presentation are included below. The Company will also host a virtual investor and analyst event today, September 20, 2021 at 8:30 AM ET, to review the updated Phase 1 data evaluating the investigational combination of UKONIQ ® (umbralisib) and ublituximab (U2) plus venetoclax presented at iwCLL, as well as provide an overview of the ULTRA-V Phase 2/3 trial. Michael S. Weiss, the Company”s Chairman and Chief Executive Officer, stated, “The iwCLL conference this past weekend was an exciting meeting, where we were able to share data from four combination trials, including updated data from our Phase 1/2 study of U2 plus venetoclax. Our goal has been to develop combination therapies utilizing U2 as a backbone and we believe the data presented this weekend showcase the breadth of the program, which includes combinations with targeted therapy as well as immunotherapy.
— Benzinga


TG Therapeutics: Amid Market Overreaction Is An Opportunity

Thursday, 16 September 2021, 02:39:25
No summary available.
— Seeking Alpha


TG Therapeutics Recaps Schedule of Upcoming Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)

Monday, 13 September 2021, 15:21:00
Investor & Analyst Virtual Event to Discuss Phase 1 U2 + Venetoclax Data to be held Monday, September 20, 2021 at 8:30 AM ET Investor & Analyst Virtual Event to Discuss Phase 1 U2 + Venetoclax Data to be held Monday, September 20, 2021 at 8:30 AM ET
— Intrado Digital Media


Trading broker recommendation

We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €250 by bank
Description: Capital.com offer a large number of stocks for trading. Register an account today and check if they have TGTX available or trade one of the many other CFD stocks they have.
Risk warning: 67.7% of retail investor accounts lose money when trading CFDs with Capital.